Compass Therapeutics Stock Math Operators Highest value over a specified period

CMPX Stock  USD 5.19  -0.40  -7.16%   
Use the math operators workspace to apply Highest value over a specified period operator and other studies to Compass Therapeutics. This view tracks relative price relationships across paired instruments to support structured performance interpretation without implying advice.Enter Time Period to generate the indicator output.

The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Highest value over a specified period line plots max value of Compass Therapeutics price series.

Compass Therapeutics Technical Analysis Modules

Most technical analysis of Compass Therapeutics help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Compass from various momentum indicators to cycle indicators. When you analyze Compass charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

Stock Overview, Methodology & Data Sources

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company was founded in 2014 and is headquartered in Boston, Massachusetts. Compass Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 24 people. A high-level view of Compass Therapeutics emphasizes earnings durability, balance-sheet flexibility, and competitive positioning. Current metrics include P/B of 4.73. Compass Therapeutics has a market cap of 994.25 M, ROE of -41.29%.

Methodology

Unless otherwise specified, financial data for Compass Therapeutics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Compass (USA Stocks:CMPX) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: The dataset for Compass Therapeutics incorporates public filings and market reference sources and official institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Some inputs may not update instantaneously. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.

Analyst Sources

Compass Therapeutics is covered by 16 analysts. 8 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include J.P. Morgan, Stifel, BMO Capital Markets, Oppenheimer & Co., Citigroup, RBC Capital Markets, Wells Fargo Securities, Evercore ISI, among others. Updates may occur throughout the day.

This content is curated and reviewed by:

Ellen Johnson - Member of Macroaxis Editorial Board

Align your values with your investing style

Using Compass Therapeutics inside a theme workflow gives investors a structured way to compare related stocks, funds, ETFs, and crypto assets before allocating capital. The practical benefit is that the selected idea can be tuned either for higher upside or for tighter risk control.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Trending Themes

If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment.
Momentum Idea
Momentum
Invested few shares
Investor Favorites Idea
Investor Favorites
Invested over 20 shares
Macroaxis Index Idea
Macroaxis Index
Invested over 60 shares
Cash Cows Idea
Cash Cows
Invested few shares
Social Domain Idea
Social Domain
Invested few shares
Advertising Idea
Advertising
Invested few shares
Macroaxis Picks Idea
Macroaxis Picks
Invested few shares
Impulse Idea
Impulse
Invested over 200 shares
Artificial Intelligence Idea
Artificial Intelligence
Invested few shares
FinTech Idea
FinTech
Invested over 20 shares
Blockchain Idea
Blockchain
Invested few shares

More Resources for Compass Stock Analysis

Reviewing Compass Therapeutics commonly begins with financial statements and performance trends. Key ratios help frame profitability, efficiency, and growth context for Compass Therapeutics Stock. Below are reports that help frame Compass Therapeutics Stock in context:
Compass Therapeutics has a market cap of 994.25 M, ROE of -41.29%. See Trending Equities for portfolio-level analysis. This suggests a position in Compass Therapeutics across the allocation. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Learn how to buy and trade Compass Stock using our step-by-step How to Buy Compass Therapeutics guide.
Analysis related to Compass Therapeutics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
 Earnings Share
-0.45
 Return On Assets
-0.25
 Return On Equity
-0.41
Investors evaluate Compass Therapeutics using market value and book value, each describing different facets of the business. Compass Therapeutics' market capitalization is 994.25 M. With a P/B ratio of 4.73, the market values Compass Therapeutics well above its book equity. Enterprise value stands at 784.22 M. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
The concept of value for Compass Therapeutics differs from its quoted price, since each reflects a different lens. For Compass Therapeutics, key inputs include a P/B ratio of 4.73, and ROE of -41.29%. By contrast, market price reflects the level where buyers and sellers transact.